08 January 2021
Visiongain has published a new report on Biological Drug API Manufacturing Services Market Report 2021-2031: Forecasts by Manufacturing Type (Outsourced, In-house), by Expression Platform (Mammalian Cell Cultures, Microbial Fermentations, Others), by Application (Vaccines, MABs, Insulin Analogues, Interferon Therapies, Human Growth Hormones, Other Therapeutic Areas) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Biological Drug API Manufacturing Companies AND COVID-19 Recovery Scenarios.
The global biological drug API manufacturing services market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to Visiongain analysis, global biological drug API manufacturing services market is estimated to be valued at US$ xx million in 2020. The market is expected to witness a CAGR of xx% from 2021 to 2026 and is expected to reach US$ xx million in 2026 from its previous value of US$ xx million in 2021. Visiongain further anticipates that the global market will reach US$ xx million in 2031 while growing at a CAGR of xx% from 2021 to 2031.
Which Factors are Fuelling Biological Drug API Manufacturing Services Industry Growth?
• Biological Patent Expirations to Fuel Market Growth
• Growing Investments in Orphan Drugs
• Outsourcing as a Driver for Market Growth
• Emerging Economies to Offer Lucrative Growth Opportunities
• Single Use Technology will Become Essential Over the Next Decade
Which Factors are Restraining Biological Drug API Manufacturing Services Industry Growth?
• Manufacturing APIs for Biologics to Restrain Market Growth
• Pricing Pressure to Impede Market Growth Through 2031
• Regulatory Scenarios to Restrain Market Growth
• Excessive Production is Projected to Impede Market Growth
• API Production is a Challenging Task
Emerging Economies to Fuel Biological Drug API Manufacturing Services Market Growth Through 2031
Between 2021 and 2031, the Indian biological drug API manufacturing services submarket will grow with the highest CAGR of 16.2%. However, in 2020, this submarket was valued at US$210.6 million, indicating the small number of companies participating in this market. Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market. Biocon is an Indian biopharmaceutical manufacturer of generic APIs that are sold in the US and EU markets, and additionally sold domestically in Indian market. In June 2019, Biocon received the European drug regulatory agency's approval for its facilities in Bengaluru, enabling it to continue and enhance its biosimilar production for the European market. The company received the certificate of GMP compliance from EMA for its Biologics Drug Product and Drug Substance facilities at Biocon Park, Bengaluru post inspection in March 2019. From the middle of the forecast period, there will be greater development of novel biologics in India, although many companies developing these products will already have an established presence in the biosimilars industry and therefore will have their own manufacturing facilities. By 2031, the Indian submarket will be worth US$ 1,076.7 million.
API Production is a Challenging Task
The process behind API production or complex as large molecules such as monoclonal antibodies are difficult to synthesize and take a lot of time and effort to produce. It often requires a multi-step process which is long and needs a lot of financial investment. However monoclonal antibodies also represent the most lucrative market as they can be used in biosimilars. Visiongain expects many of the biotech CMO currently in the market need to focus on the production and manufacturing of monoclonal antibodies for the future.
Some of the companies profiled in the report include Bristol-Myers Squibb Co., Samsung Biologics, AbbVie, GSK Biopharmaceuticals, Lonza Group Ltd., NEKTAR THERAPEUTICS, Boehringer, Patheon N.V., Cytovance Biologics, and Fujifilm Diosynth Biotechnologies, among others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.